Gammanorm

Gammanorm (Human Normal Immunoglobulin) is a sterile, purified preparation of human immunoglobulin (IgG) obtained from the plasma of healthy donors. It is primarily used to provide passive immunity to individuals who are at risk of or are suffering from immunodeficiency disorders. By supplying essential antibodies, Gammanorm helps the body fight infections caused by bacteria and viruses, offering both prophylactic and therapeutic benefits.
This medication is particularly effective for patients with primary immunodeficiency diseases (PIDs), including common variable immunodeficiency (CVID) and X linked agammaglobulinemia (XLA), where the immune system cannot produce sufficient antibodies. It is also utilized in secondary immunodeficiencies caused by chemotherapy, bone marrow transplantation, or chronic lymphocytic leukemia. Administered intravenously or subcutaneously, the dosage and frequency of Gammanorm are tailored according to the patient’s weight, clinical condition, and serum IgG levels, ensuring optimal protection against infections.
Gammanorm works by supplying ready made antibodies, enhancing the body’s immune defense and reducing the frequency and severity of infections. It is generally well tolerated, though some patients may experience mild side effects such as headache, fever, chills, or injection site reactions. Serious reactions are rare but require immediate medical attention.
As a high quality human plasma product, Gammanorm is manufactured under strict regulatory standards to ensure purity, safety, and efficacy. Regular monitoring during treatment helps maintain adequate immunoglobulin levels and prevent complications. With its proven immunoprotective properties, Gammanorm plays a vital role in improving the quality of life for patients with compromised immune systems, supporting their ability to resist infections effectively.